Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery

Current Vascular Pharmacology

Volumn 11, Issue 6, 2013, Pages 988-991

  Tagarakis, Georgios I ^a   Aidonidis, Isaac ^a   Daskalopoulou, Stella S ^b   Simopoulos, Vassilios ^a   Liouras, Vassilios ^a   Daskalopoulos, Marios E ^c   Parisis, Charalampos ^a   Papageorgiou, Kiriaki ^a   Skoularingis, Ioannis ^a   Triposkiadis, Filippos ^a   Molyvdas, Paschalis Adam ^a   Tsilimingas, Nikolaos B ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b MCGILL UNIVERSITY   (Canada)

^c THRIASIO GENERAL HOSPITAL   (Greece)

Author keywords

Atrial fibrillation; Coronary artery bypass graft surgery; Postoperative; Prevention; Ranolazine

Indexed keywords

RANOLAZINE;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; CHOLANGITIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY SURGERY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTUBATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; ON PUMP CORONARY SURGERY; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; SINGLE BLIND PROCEDURE; SINUS RHYTHM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACETANILIDES; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CORONARY ARTERY BYPASS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84893518835     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111106140128123506     Document Type: Article

References (29)

1. Mitchell LB; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol 2011; 27: 91-7.
2. Echahidi N, Pibarot P, O'Hara et al. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008; 51: 793-801.
3. Sabzi F, Zokaei AH, Moloudi AR. Predictors of atrial fibrillation following coronary arery bypass grafting. Clin Med Insights Cardiol 2011; 5: 67-75.
4. Hogue CW, Hyder ML. Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment. Ann Thorac Surg 2000; 69: 300-6.
5. Cao L, Li Q, Bi Q et al. Risk factors for recurrent stroke after coronary artery bypass grafting. J Cardiothorac Surg 2011; 6: 157.
6. Banach M, Kourliouros A, Reinhart KM et al. Postoperative atrial fibrillation-what do we really know? Curr Vasc Pharmacol 2010; 8: 553-72.
7. Banach M, Mariscalco G, Ugurlucan M et al. The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation-still underestimated opponent. Europace 2008; 10: 1266-70.
8. Bandeali SJ, Kayani WT, Lee VV et al. Outcomes of Preoperative Angiotensin-Converting Enzyme Inhibitor Therapy in Patients Undergoing Isolated Coronary Artery Bypass Grafting. Am J Cardiol 2012; 110: 919-23.
9. Radaelli G, Bodanese LC, Guaragna JC et al. The use of inhibitors of angiotensin-converting enzyme and its relation to events in the postoperative period of CABG. Rev Bras Cir Cardiovasc 2011; 26: 373-9.
10. Ouzounian M, Buth KJ, Valleva L et al. Impact of preoperative angiotensin-converting enzyme inhibitor use on clinical outcomes after cardiac surgery. Ann Thorac Surg 2012; 93: 559-64.
11. Rostagno C. Atrial fibrillation in patients undergoing surgical revascularization: an update on pharmacologic prophylaxis. Cardiovasc Hematol Agents Med Chem 2012 May 30. [Epub ahead of print].
12. Dimmer C, Tavernier R, Gjorgov N et al. Variations of autonomic tone preceding onset of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 1998; 82: 22-5.
13. McCormack JG, Stanley WC, Wolff AA. Ranolazine: a novel metabolic modulator for the treatment of angina. Gen Pharmacol 1998; 30: 639-45.
14. Phelps CE, Buysman EK, GomezRey G. Costs and Clinical Outcomes Associated with Use of Ranolazine for Treatment of Angina. Clin Ther 2012; 34: 1395-407.
15. Bonadei I, Vizzardi E, Quinzani F et al. Effects of ranolazine on cardiovascular system. Recent Pat Cardiovasc Drug Discover 2011; 6: 215-21.
16. Vizzardi E, D'Aloia A, Quinzani F et al. A focus on antiarrhythmic properties of ranolazine. J Cardiovasc Phramacol Ther 2012 Apr 6. [Epub ahead of print].
17. Hancox JC, Doggrell SA. Perspective: does ranolazine have potential for the treatment of atrial fibrillation? Expert Opin Investig Drugs 2010; 19: 1465-74.
18. Aidonidis I, Doulas K, Hatziefthimiou A et al. Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits. J Cardiovasc Pharmacol Ther 2012 Aug 7. [Epub ahead of print].
19. Sicouri S, Glass A, Belardinelli L et al. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008; 5: 1019-26.
20. Carvas M, Nascimento BC, Acar M et al. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart. J Cardiovas Pharmacol 2010; 55: 286-91.
21. Nieminen T, Nanbu DY, Datti IP et al. Antifibrillatory effect of ranolazine during severe stenosis in the intact porcine model. Heart Rhythm 2011; 8: 608-14.
22. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current ranolazine. Heart 2006; 96: 6-14.
23. Wilson SR, Scirica BM, Braunwald E et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency with Ranolazine for less Ischemia in non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009; 53: 1510-6.
24. Arnold SV, Morrow DA, Wang K et al. Effects of ranolazine on diseas-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes 2008; 1: 107-15.
25. Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291: 309-16.
26. Scirica BM, Morrow DA, Hod H et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116: 1647-52.
27. Dhalla AK, Wang WQ, Dow J et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2009; 297: H1923-9.
28. Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2011; 108: 673-6.
29. Burashnikov A, Antzelevitch C. Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation. Future Cardiol 2011; 7: 733-7.